Scinai Immunotherapeutics Secures $2.61 Million Financing Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2025
0mins
Should l Buy SCNI?
Scinai Immunotherapeutics Ltd. shares rose by 11.30% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment.
The company has entered into a securities purchase agreement with institutional investors to sell 5,208,333 American Depositary Shares (ADSs) at $0.48 each, expected to generate approximately $2.61 million. This financing will support the expansion of its CDMO platform and immunotherapy pipeline investments. Additionally, a warrant inducement agreement has been established with an existing investor for the immediate exercise of 229,310 existing warrants, enhancing liquidity and demonstrating the company's commitment to growth in the biopharmaceutical sector.
This financing agreement is a strategic move that not only boosts the company's liquidity but also positions Scinai for future growth in a competitive market, indicating strong confidence from investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCNI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCNI
About SCNI
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scinai Immunotherapeutics Secures $2.61M in Securities Purchase Agreement
- Financing Agreement: Scinai Immunotherapeutics has signed a securities purchase agreement with institutional investors to sell 5.21 million American Depositary Shares (ADS) at $0.48 each, expected to generate approximately $2.61 million, enhancing liquidity for future growth initiatives.
- Warrant Issuance: The company will issue Series A and Series B warrants to purchase 5.21 million ADSs at exercise prices of $0.48 and $0.55, respectively, with terms of two and five years, which will further improve capital structure flexibility.
- Investor Incentives: Scinai has entered into a warrant inducement agreement with an existing investor for the immediate exercise of 229,310 ADS warrants, in exchange for new warrants to purchase 458,621 ADSs, thereby boosting investor confidence and engagement.
- Planned Use of Funds: The company intends to utilize the net proceeds alongside existing cash resources to support the expansion of its Contract Development and Manufacturing Organization (CDMO) platform, advance customer programs, and selectively invest in its immunotherapy pipeline, demonstrating a strategic focus on future growth.
See More
Scinai Immunotherapeutics Completes Financing Agreement
- Financing Agreement Reached: Scinai Immunotherapeutics has entered into a securities purchase agreement with institutional investors for the sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 each, expected to generate approximately $2.61 million to support the expansion of its CDMO platform and immunotherapy pipeline investments.
- Warrant Inducement Arrangement: The company has also engaged in a warrant inducement agreement with an existing investor for the immediate exercise of 229,310 existing warrants for cash, providing the investor with 458,621 new warrants, thereby enhancing liquidity.
- Strategic Growth Support: This financing will provide essential funding for advancing customer programs and expanding the CDMO platform, indicating the company's ongoing commitment to investment in the biopharmaceutical sector to enhance market competitiveness.
- Expected Transaction Completion: The transactions are anticipated to close around April 27, 2026, subject to customary closing conditions, reflecting the company's active engagement in capital markets and confidence in future growth.
See More
Scinai Secures $2.61 Million Financing to Expand CDMO Platform
- Financing Size: Scinai Immunotherapeutics has entered into a securities purchase agreement to sell 5,208,333 American Depositary Shares (ADSs) at $0.48 each, with total expected proceeds of approximately $2.61 million, aimed at supporting the expansion of its contract development and manufacturing organization (CDMO) platform.
- Use of Proceeds: The company intends to combine the net proceeds with existing cash resources to advance customer programs and continue selective investments in its immunotherapy pipeline, thereby enhancing its market competitiveness and growth potential.
- Warrant Inducement Agreement: Scinai has also entered into a warrant inducement agreement with an existing investor, allowing for the immediate exercise of existing warrants to purchase 229,310 ADSs, while providing new warrants, which further enhances liquidity to support future R&D and market expansion.
- Transaction Timeline: The closing of the transaction is expected to occur on April 27, 2026, subject to customary closing conditions, and successful completion will provide the necessary funding support to help the company achieve its growth strategy and business development objectives.
See More
Scinai Immunotherapeutics Completes CDMO Business Reorganization
- Strategic Reorganization Completed: Scinai Immunotherapeutics has announced the completion of a strategic reorganization of its CDMO business, establishing a dedicated CDMO platform and streamlining its R&D organization to enhance capital efficiency and operational focus, thereby creating value for stakeholders.
- CDMO Platform Development: The newly formed Scinai Biopharma Services Ltd. consolidates all CDMO-related operations, including personnel, infrastructure, and customer contracts, creating a fully integrated CDMO platform capable of supporting customer programs from early-stage development through to commercial production.
- Lean R&D Structure: By transferring CDMO-related assets and personnel, Scinai Immunotherapeutics has achieved a significantly leaner R&D structure, allowing non-core infrastructure and operational functions to directly support revenue-generating activities, thus improving capital efficiency.
- 2026 Strategic Goals: The company has set strategic objectives for 2026 aimed at driving growth in the biopharmaceutical sector through a focused CDMO business and efficient R&D pipeline, while collaboration with Recipharm is expected to further enhance its market competitiveness.
See More
Scinai Immunotherapeutics Completes CDMO Business Reorganization
- Strategic Reorganization: Scinai Immunotherapeutics has completed a strategic reorganization of its CDMO business, establishing a dedicated CDMO platform while streamlining its R&D organization to enhance capital efficiency and operational focus, thereby creating value for stakeholders.
- CDMO Platform Development: The newly formed Scinai Biopharma Services Ltd. consolidates all CDMO-related operations, including personnel, infrastructure, and customer contracts, creating a fully integrated CDMO platform designed to support customer programs throughout the entire lifecycle.
- Revenue Targets: The company anticipates approximately $5 million in CDMO revenues for 2026, leveraging its collaboration with Recipharm to expand its customer base in the U.S. and Europe, thus driving business growth.
- Optimized R&D Structure: Following the reorganization, Scinai Immunotherapeutics operates with a leaner R&D structure focused on high-value development projects, enhancing capital allocation efficiency through non-dilutive funding strategies to support early-stage development.
See More
Scinai Immunotherapeutics Financial Overview
- Cash Position: As of December 31, 2025, Scinai Immunotherapeutics reported cash, cash equivalents, and restricted cash totaling $1.8 million, down from $2.1 million as of December 31, 2024, indicating challenges in liquidity management.
- Revenue Growth: For FY 2025, Scinai achieved revenue of $1.3 million, representing an 85.7% year-over-year increase, which highlights significant progress in market demand and product promotion, potentially enhancing its attractiveness for future investments.
- Nasdaq Notice: The company received a notice from Nasdaq regarding minimum bid price requirements, which could negatively impact its stock price and market confidence, compelling the company to take measures to maintain its listing status.
- Financial Transparency: The financial information released by the company reveals a contradiction between revenue growth and cash flow management, necessitating stronger financial strategies to ensure sustainable development moving forward.
See More
Scinai Immunotherapeutics Secures $2.61M in Securities Purchase Agreement
- Financing Agreement: Scinai Immunotherapeutics has signed a securities purchase agreement with institutional investors to sell 5.21 million American Depositary Shares (ADS) at $0.48 each, expected to generate approximately $2.61 million, enhancing liquidity for future growth initiatives.
- Warrant Issuance: The company will issue Series A and Series B warrants to purchase 5.21 million ADSs at exercise prices of $0.48 and $0.55, respectively, with terms of two and five years, which will further improve capital structure flexibility.
- Investor Incentives: Scinai has entered into a warrant inducement agreement with an existing investor for the immediate exercise of 229,310 ADS warrants, in exchange for new warrants to purchase 458,621 ADSs, thereby boosting investor confidence and engagement.
- Planned Use of Funds: The company intends to utilize the net proceeds alongside existing cash resources to support the expansion of its Contract Development and Manufacturing Organization (CDMO) platform, advance customer programs, and selectively invest in its immunotherapy pipeline, demonstrating a strategic focus on future growth.
See More
Scinai Immunotherapeutics Completes Financing Agreement
- Financing Agreement Reached: Scinai Immunotherapeutics has entered into a securities purchase agreement with institutional investors for the sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 each, expected to generate approximately $2.61 million to support the expansion of its CDMO platform and immunotherapy pipeline investments.
- Warrant Inducement Arrangement: The company has also engaged in a warrant inducement agreement with an existing investor for the immediate exercise of 229,310 existing warrants for cash, providing the investor with 458,621 new warrants, thereby enhancing liquidity.
- Strategic Growth Support: This financing will provide essential funding for advancing customer programs and expanding the CDMO platform, indicating the company's ongoing commitment to investment in the biopharmaceutical sector to enhance market competitiveness.
- Expected Transaction Completion: The transactions are anticipated to close around April 27, 2026, subject to customary closing conditions, reflecting the company's active engagement in capital markets and confidence in future growth.
See More
Scinai Secures $2.61 Million Financing to Expand CDMO Platform
- Financing Size: Scinai Immunotherapeutics has entered into a securities purchase agreement to sell 5,208,333 American Depositary Shares (ADSs) at $0.48 each, with total expected proceeds of approximately $2.61 million, aimed at supporting the expansion of its contract development and manufacturing organization (CDMO) platform.
- Use of Proceeds: The company intends to combine the net proceeds with existing cash resources to advance customer programs and continue selective investments in its immunotherapy pipeline, thereby enhancing its market competitiveness and growth potential.
- Warrant Inducement Agreement: Scinai has also entered into a warrant inducement agreement with an existing investor, allowing for the immediate exercise of existing warrants to purchase 229,310 ADSs, while providing new warrants, which further enhances liquidity to support future R&D and market expansion.
- Transaction Timeline: The closing of the transaction is expected to occur on April 27, 2026, subject to customary closing conditions, and successful completion will provide the necessary funding support to help the company achieve its growth strategy and business development objectives.
See More
Scinai Immunotherapeutics Completes CDMO Business Reorganization
- Strategic Reorganization Completed: Scinai Immunotherapeutics has announced the completion of a strategic reorganization of its CDMO business, establishing a dedicated CDMO platform and streamlining its R&D organization to enhance capital efficiency and operational focus, thereby creating value for stakeholders.
- CDMO Platform Development: The newly formed Scinai Biopharma Services Ltd. consolidates all CDMO-related operations, including personnel, infrastructure, and customer contracts, creating a fully integrated CDMO platform capable of supporting customer programs from early-stage development through to commercial production.
- Lean R&D Structure: By transferring CDMO-related assets and personnel, Scinai Immunotherapeutics has achieved a significantly leaner R&D structure, allowing non-core infrastructure and operational functions to directly support revenue-generating activities, thus improving capital efficiency.
- 2026 Strategic Goals: The company has set strategic objectives for 2026 aimed at driving growth in the biopharmaceutical sector through a focused CDMO business and efficient R&D pipeline, while collaboration with Recipharm is expected to further enhance its market competitiveness.
See More
Scinai Immunotherapeutics Completes CDMO Business Reorganization
- Strategic Reorganization: Scinai Immunotherapeutics has completed a strategic reorganization of its CDMO business, establishing a dedicated CDMO platform while streamlining its R&D organization to enhance capital efficiency and operational focus, thereby creating value for stakeholders.
- CDMO Platform Development: The newly formed Scinai Biopharma Services Ltd. consolidates all CDMO-related operations, including personnel, infrastructure, and customer contracts, creating a fully integrated CDMO platform designed to support customer programs throughout the entire lifecycle.
- Revenue Targets: The company anticipates approximately $5 million in CDMO revenues for 2026, leveraging its collaboration with Recipharm to expand its customer base in the U.S. and Europe, thus driving business growth.
- Optimized R&D Structure: Following the reorganization, Scinai Immunotherapeutics operates with a leaner R&D structure focused on high-value development projects, enhancing capital allocation efficiency through non-dilutive funding strategies to support early-stage development.
See More
Scinai Immunotherapeutics Financial Overview
- Cash Position: As of December 31, 2025, Scinai Immunotherapeutics reported cash, cash equivalents, and restricted cash totaling $1.8 million, down from $2.1 million as of December 31, 2024, indicating challenges in liquidity management.
- Revenue Growth: For FY 2025, Scinai achieved revenue of $1.3 million, representing an 85.7% year-over-year increase, which highlights significant progress in market demand and product promotion, potentially enhancing its attractiveness for future investments.
- Nasdaq Notice: The company received a notice from Nasdaq regarding minimum bid price requirements, which could negatively impact its stock price and market confidence, compelling the company to take measures to maintain its listing status.
- Financial Transparency: The financial information released by the company reveals a contradiction between revenue growth and cash flow management, necessitating stronger financial strategies to ensure sustainable development moving forward.
See More
